These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Trial of tipranavir versus darunavir in treatment-experienced patients enrolling. AIDS Patient Care STDS; 2007 Aug; 21(8):6-3. PubMed ID: 17902242 [No Abstract] [Full Text] [Related]
24. Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study. Markowitz M; Slater LN; Schwartz R; Kazanjian PH; Hathaway B; Wheeler D; Goldman M; Neubacher D; Mayers D; Valdez H; McCallister S J Acquir Immune Defic Syndr; 2007 Aug; 45(4):401-10. PubMed ID: 17554217 [TBL] [Abstract][Full Text] [Related]
25. Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST. Raffi F; Battegay M; Rusconi S; Opravil M; Blick G; Steigbigel RT; Kraft M; Neubacher D; Sabo JP AIDS; 2007 Sep; 21(14):1977-80. PubMed ID: 17721109 [TBL] [Abstract][Full Text] [Related]
26. Impact of baseline protease genotype and phenotype on the response to darunavir outside clinical trials. Poveda E; Vispo E; Pattery T; de Mendoza C; Villacian J; Soriano V J Antimicrob Chemother; 2007 Dec; 60(6):1411-3. PubMed ID: 17911388 [No Abstract] [Full Text] [Related]
27. [New protease inhibitor for PI pretreated patients. Tipranavir targets also multiresistant viruses]. MMW Fortschr Med; 2004 Apr; 146 Spec No 1():60-1. PubMed ID: 15373052 [No Abstract] [Full Text] [Related]
28. Meeting notes from ICAAC. Ritonavir-boosted tipranavir proves beneficial in treatment-experienced patients. Feinberg J AIDS Clin Care; 2005 Jan; 17(1):5-6. PubMed ID: 15717371 [No Abstract] [Full Text] [Related]
33. Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents. Salazar JC; Cahn P; Yogev R; Negra MD; Castelli-Gattinara G; Fortuny C; Flynn PM; Giaquinto C; Ruan PK; Smith ME; Mikl J; Jelaska A; AIDS; 2008 Sep; 22(14):1789-98. PubMed ID: 18753862 [TBL] [Abstract][Full Text] [Related]
34. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity. Yeni P J Acquir Immune Defic Syndr; 2003 Sep; 34 Suppl 1():S91-4. PubMed ID: 14562864 [TBL] [Abstract][Full Text] [Related]
35. Aptivus in the hotseat. Excerpts from the FDA hearings. Huff B GMHC Treat Issues; 2005; 19(5-6):6-8. PubMed ID: 16193577 [No Abstract] [Full Text] [Related]
36. Estimated extent of cross-resistance to ritonavir-boosted protease inhibitors among protease inhibitors-experienced patients: implications for tipranavir use. Gallego O; de Mendoza C; Corral A; Barrios A; Soriano V AIDS Patient Care STDS; 2005 Feb; 19(2):67-9. PubMed ID: 15716637 [No Abstract] [Full Text] [Related]
37. Cross-resistance within the protease inhibitor class. Race E Antivir Ther; 2001; 6 Suppl 2():29-36. PubMed ID: 11678476 [No Abstract] [Full Text] [Related]
38. New protease inhibitors and non-nucleoside reverse transcriptase inhibitors. Lascar M; Cartledge JD J HIV Ther; 2008 Jun; 13(2):40-4. PubMed ID: 18953273 [No Abstract] [Full Text] [Related]
39. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. Baxter JD; Schapiro JM; Boucher CA; Kohlbrenner VM; Hall DB; Scherer JR; Mayers DL J Virol; 2006 Nov; 80(21):10794-801. PubMed ID: 16928764 [TBL] [Abstract][Full Text] [Related]